CRIS Current Research Information System

CECI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.902
EU - Europa 2.735
AS - Asia 1.399
AF - Africa 235
SA - Sud America 8
OC - Oceania 2
Totale 8.281
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.891
GB - Regno Unito 868
VN - Vietnam 708
IT - Italia 438
SE - Svezia 404
CN - Cina 393
DE - Germania 357
IN - India 178
IE - Irlanda 134
RU - Federazione Russa 118
FR - Francia 107
TG - Togo 85
EE - Estonia 74
ZA - Sudafrica 74
JO - Giordania 57
CH - Svizzera 53
CI - Costa d'Avorio 51
FI - Finlandia 51
UA - Ucraina 38
BG - Bulgaria 37
IR - Iran 22
NG - Nigeria 22
SG - Singapore 16
BE - Belgio 15
CA - Canada 9
ES - Italia 9
RO - Romania 8
AT - Austria 5
NL - Olanda 5
BR - Brasile 4
PL - Polonia 4
KR - Corea 3
MY - Malesia 3
PT - Portogallo 3
SA - Arabia Saudita 3
TH - Thailandia 3
CL - Cile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
JP - Giappone 2
LB - Libano 2
PK - Pakistan 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
CM - Camerun 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HR - Croazia 1
ID - Indonesia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MX - Messico 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SC - Seychelles 1
TR - Turchia 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 8.281
Salva come PNG Salva come JPEG
Città #
Southend 824
Fairfield 602
Chandler 399
Ashburn 335
Seattle 266
Wilmington 265
Houston 262
Woodbridge 258
Cambridge 229
Princeton 180
Dublin 134
Ann Arbor 132
Dong Ket 124
Bologna 97
Westminster 89
Lomé 85
Berlin 70
Nanjing 70
Padova 68
Amman 57
Abidjan 51
Helsinki 49
Beijing 45
Bern 45
Shenyang 40
Jinan 35
Sofia 34
Florence 33
Saint Petersburg 33
Turin 31
San Diego 30
Medford 29
Hebei 27
Nanchang 27
Bremen 25
New York 25
Changsha 24
Redwood City 23
Abeokuta 20
Norwalk 15
Dearborn 14
Los Angeles 14
Rome 14
Tianjin 14
Brussels 13
Falls Church 12
Jiaxing 12
Milan 12
Zhengzhou 11
Des Moines 9
Taiyuan 9
Haikou 8
Kuban 8
Redmond 8
Toronto 8
Venezia 8
Fuzhou 7
Olalla 7
Taizhou 7
Bari 6
Bühl 6
Lanzhou 6
Zanjan 6
Barcelona 5
Boardman 5
Guangzhou 5
Hangzhou 5
Hefei 5
Kumar 5
London 5
Mülheim 5
Naples 5
Phoenix 5
Torino 5
Amsterdam 4
Mountain View 4
Ningbo 4
Palermo 4
Pune 4
Singapore 4
Brescia 3
Camerino 3
Clearwater 3
Conegliano 3
Kuala Lumpur 3
Lausanne 3
Leawood 3
Moscow 3
Nuremberg 3
Rio Saliceto 3
Sacramento 3
San Francisco 3
Almería 2
Atlanta 2
Atrani 2
Buffalo 2
Casalecchio Di Reno 2
Chengdu 2
Chicago 2
Costa Mesa 2
Totale 5.537
Salva come PNG Salva come JPEG
Nome #
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 163
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 161
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 148
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 144
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 143
68Ga-PSMA PET/CT for restaging prostate cancer after definitive therapy: Results of a prospective single-center trial 143
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 142
11C-Choline PET/CT for Restaging of Bladder Cancer 139
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 137
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and midterm follow-up 135
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 131
18F-FACBC PET/CT in comparison to 11c-choline for the detection of prostate cancer relapse after radical prostatectomy: A perspective study in 50 patients 130
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 129
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 128
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 126
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 124
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 122
How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? 120
null 119
18f-fdg pet/ct for restaging gastric cancer after surgical resection 119
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 117
18F-FACBC PET/CT VS. 11C-CHOLINE FOR THE DETECTION OF PROSTATE CANCER RELAPSE AFTER RADICAL TREATMENT 114
null 113
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 112
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 111
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 108
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence 106
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. 105
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: Impact on salvage radiotherapy planning 105
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 103
New radiopharmaceutical markers for metabolism and receptor 100
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 100
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 98
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. 98
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. 97
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 97
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 96
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 96
PET/CT and prostate cancer 94
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 92
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 91
68Ga-PSMA PET/CT in prostate cancer 91
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 91
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. 90
PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications 90
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. 89
New aspects of molecular imaging in prostate cancer. 88
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. 88
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT IN COMPARISON WITH CONTRASTENHANCED CT IN THE PREOPERATIVE LYMPH-NODE STAGING OF BLADDER CANCER USING THE PATHOLOGICAL SPECIMENS AS REFERENCE STANDARD 87
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 87
Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. 83
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT COMPARED TO CONTRASTENHANCED CT IN THE POSTOPERATIVE RESTAGING OF RECURRENT BLADDER CANCER: ANALYSIS OF 20 CONSECUTIVE PATIENTS 82
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 81
Clinical impact of 11C-Choline PET/CT in recurrent prostate cancer patients after radical therapy: Which is the real impact on treatment decisions? 80
Reply: Comparison of68Ga-PSMA-11 and18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way 80
Comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence 79
IL RUOLO DELLA 11C-COLINA PET/CT IN PAZIENTI CON RECIDIVA BIOCHIMICA DOPO PROSTATECTOMIA RADICALE E CARCINOMA PROSTATICO ORMONO-RESISTENTE SOTTOPOSTI A TERAPIA DI DEPRIVAZIONE ANDROGENICA 79
Molecular Imaging and Precision Medicine in Prostate Cancer 78
Detection of sarcomatoid lung metastasis with 68GA-PSMA PET/CT in a patient with prostate cancer 78
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 77
A new type of prostate cancer imaging. Will64CuCl2PET/CT flourish or vanish? 76
Role of 11C-Choline PET/CT in androgen sensitive prostate cancer patients treated with intermittent ADT: A sequential PET/CT study after therapy interruption 75
null 73
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 73
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial 72
Therapy assessment in prostate cancer using choline and PSMA PET/CT. 71
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. 71
PET/CT in prostate cancer 71
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: preliminary results 70
68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report 70
PREOPERATIVE 11C-CHOLINE PET-CT IN INTERMEDIATE, HIGH RISK AND VERY HIGH RISK PROSTATE CANCER PATIENTS: IS THERE STILL ANY ROOM LEFT FOR IT? 69
Role of 18F-FDG PET/CT in the restaging of patients affected by clear cell renal carcinoma 69
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 69
Ga-68-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels< 2 ng/mL 69
Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings. 69
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68 Ga-PSMA-11 PET/CT 68
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. 68
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 65
The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? 62
Yttrium 90 Intra Arterial Radioembolization Therapy of Unresectable Intrahepatic Cholangiocarcinoma: 5 Year Experience at a Single Center 61
Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. 59
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 58
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals 57
Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders 55
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 54
New radiopharmaceutical Markers for Matebolism and receptor 53
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply 52
PSMA-PET/CT imaging in prostate cancer: why and when 47
Aetna and 68 Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others" 43
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. 39
Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer 39
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: Nodal oligorecurrent prostate cancer 38
Stardardisation of PSMA images interpretation: why do we need it? 37
SEM, TEM, and IHC Analysis of the Sinus Node and Its Implications for the Cardiac Conduction System 22
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 11
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis 11
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial 8
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer 6
Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications 6
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml 4
Totale 8.544
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.251
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.251
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.270 318 65 7 121 209 216 288 307 350 148 138 103
2020/20211.120 254 64 36 22 15 46 23 60 151 43 35 371
2021/20221.961 554 58 97 126 170 78 45 108 59 59 351 256
2022/20231.906 169 284 111 252 110 129 49 99 371 89 144 99
2023/2024528 72 82 26 50 38 84 30 29 22 39 27 29
2024/202517 17 0 0 0 0 0 0 0 0 0 0 0
Totale 8.546